April 12, 2023
Willkie represented Clovis Oncology, Inc. in the sale of its oncology drug Rubraca (rucaparib) to pharma& Schweiz GmbH in a bankruptcy 363 sale.
Clovis Oncology, Inc., a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe, and additional international markets, initiated a chapter 11 proceeding in December in order to sell its assets through a court-supervised process.
The Willkie corporate team was led by partners Thomas Mark and Erin Kinney. The bankruptcy team was led by partners Rachel Strickland and Andrew Mordkoff.
Clovis Oncology, Inc., a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe, and additional international markets, initiated a chapter 11 proceeding in December in order to sell its assets through a court-supervised process.
The Willkie corporate team was led by partners Thomas Mark and Erin Kinney. The bankruptcy team was led by partners Rachel Strickland and Andrew Mordkoff.
